Revitalising cancer trials post-pandemic: time for reform
- PMID: 36959378
- PMCID: PMC10035974
- DOI: 10.1038/s41416-023-02224-y
Revitalising cancer trials post-pandemic: time for reform
Abstract
The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.
© 2023. Crown.
Conflict of interest statement
The authors declare no competing interests.
References
-
- Cancer Research UK. Cancer in the UK 2019. London: Cancer Research UK; 2019.
-
- CRUK, ECCO, EORTC, ECRIN, ESMO, ESF, et al. Revision of the EU Clinical Trials Directive: A joint statement from non-commercial and commercial organisations. London: Cancer Research UK; 2013.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical